This study reports for the first time the development and characterization of an immunological approach to potentially targeting tumor cells undergoing EMT via the use of a recombinant yeast vaccine that expresses brachyury, a transcription factor able to drive EMT in human carcinomas [11, 12, 20]. This evidence concerns the gene TBX1 and neoplasm.